|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 |
|
| |||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. | SEC 1474 (9-02) | ||
| 1. Title of Derivative Security (Instr. 3) |
2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) |
6. Date Exercisable and Expiration Date (Month/Day/Year) |
7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
8. Price of Derivative Security (Instr. 5) |
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) |
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) |
11. Nature of Indirect Beneficial Ownership (Instr. 4) |
||||
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
| Series D 8% Convertible Preferred Stock | $ 0.2 | 06/03/2009 | C(1) | 75 | 09/15/2008 | (4) | Common Stock | 375,000 | $ 1,000 | 0 | I | By Wheaten HealthCare Partners, LP (3) | |||
| Common Stock Warrant | $ 0.25 | 06/03/2009 | J | 375,000 | 06/03/2009 | 06/03/2014 | Common Stock | 375,000 | (5) | 1,257,113 | I | By Wheaten HealthCare Partners, LP (3) | |||
| Reporting Owner Name / Address | Relationships | |||
| Director | 10% Owner | Officer | Other | |
| TREPPEL JERRY C/O ELITE PHARMACEUTICALS, INC. 165 LUDLOW AVENUE NORTHVALE, NJ 07647 |
X | |||
| /s/ Jerry Treppel | 07/01/2009 | |
| **Signature of Reporting Person | Date |
| * | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
| ** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
| (1) | The Series D 8% Convertible Preferred Stock, par value $0.01 per share (the "Series D Preferred Stock"), of the Registrant is convertible into the Registrant's common stock, par value $0.01 per share (the "Common Stock"), at a conversion price per share of $0.20. On June 3, 2009, Wheaten HealthCare Partners, LP ("Wheaten"), of which the Reporting Person is a general partner, converted 75 shares of Series D Preferred Stock resulting in the issuance to Wheaten of 375,000 shares of Common Stock. |
| (2) | Represents 375,000 shares of Common Stock issued to Wheaten upon its conversion on June 3, 2009 of 75 shares of Series D Preferred Stock and 44,059 shares of Common Stock issued to Wheaten in satisfaction of dividend obligations on the 75 shares of Series D Preferred Stock held by Wheaten from September 15, 2008 to June 3, 2009. The Reporting Person disclaims ownership of the shares, except to the extent of his pecuniary interest therein, if any. |
| (3) | Held by Wheaten HealthCare Partners, LP, of which the Reporting Person is a general partner. |
| (4) | The Series D Preferred Stock shall remain outstanding until converted to Common Stock by the holder or the Registrant pursuant to the terms thereof. |
| (5) | The Warrant was issued to Wheaten pursuant to the Conversion Agreement between the Registrant and Wheaten, dated as of April 22, 2009, in consideration of Wheaten's agreement to convert all shares of the Registrant's preferred stock held by Wheaten into Common Stock on or before the initial closing of the transactions contemplated by that certain Strategic Alliance Agreement, dated as of March 18, 2009, by and among the Registrant, on the one hand, and Epic Pharma, LLC and Epic Investments, LLC, on the other hand. The Warrant is exercisable for up to 375,000 shares of Common Stock at an exercise price per share of $0.25. The number of shares issuable upon exercise of the Warrant, and the exercise price per share thereof, is subject to adjustment pursuant to the terms of the Warrant. The Reporting Person disclaims ownership of the Warrant, and the underlying shares of Common Stock, except to the extent of his pecuniary interest therein, if any. |